Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/5/2025

Respiratory Safety Concerns with Quetiapine in Asthmatic Patients

Introduction to Quetiapine-Associated Risks

  • The British Thoracic Society guidelines state that any sedation is absolutely contraindicated in acute severe asthma, as it can worsen respiratory function 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
  • According to the British Thoracic Society guidelines, sedation is prohibited during asthma exacerbations when patients show features of severe asthma, such as respiratory rate >25 breaths/min, PEF <50% predicted, or inability to complete sentences 4, 5, 9
  • Life-threatening asthma features, including PEF <33% predicted, silent chest, exhaustion, confusion, or hypercapnia, make sedation potentially fatal 4, 5, 9

Clinical Decision-Making for Quetiapine Use

  • The British Thoracic Society guidelines recommend assessing current asthma control before considering quetiapine, and not prescribing it if any acute exacerbation features are present 1, 2, 3, 4
  • If PEF <75% predicted or nocturnal symptoms are present, the guidelines suggest deferring quetiapine until asthma is stabilized 1, 7, 8, 10

Monitoring and Safety Precautions

  • Baseline and ongoing assessment of respiratory rate, oxygen saturation, and peak expiratory flow are recommended if quetiapine is prescribed despite risks 1, 2, 3
  • Patients should have a written action plan for worsening respiratory symptoms 1, 7, 8, 10

REFERENCES